Can the Use of ADCs in Breast Cancer Teach Us About Resistance Mechanisms and Sequencing in Endometrial Cancer?
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Can the Use of ADCs in Breast Cancer Teach Us About Resistance Mechanisms and Sequencing in Endometrial Cancer?
-
ナレーター：
-
著者：
Drs Ursula A. Matulonis and Leif W. Ellisen discuss endometrial cancer and ADCs, including resistance mechanisms, ADC sequencing, what's exciting in the field, and novel payloads.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s2-ep6-2026a10008nk. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview
The Clinical Landscape of Antibody-Drug Conjugates in Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/39074933/
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Mechanisms of Resistance to Antibody-Drug Conjugates https://pubmed.ncbi.nlm.nih.gov/36831621/
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients With Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/39745368/
Single-Cell Analysis Technologies for Cancer Research: From Tumor-Specific Single Cell Discovery to Cancer Therapy https://pubmed.ncbi.nlm.nih.gov/37900181/
Spatial Transcriptomics for Tumor Heterogeneity Analysis https://pubmed.ncbi.nlm.nih.gov/35899203/
Exploring Circulating Tumor DNA (CtDNA) and Its Role in Early Detection of Cancer: A Systematic Review https://pmc.ncbi.nlm.nih.gov/articles/PMC10516512/
Current and Emerging Prognostic Biomarkers in Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/35530346/
Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34404686/
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients With Breast Cancer https://pubmed.ncbi.nlm.nih.gov/38709212/
Antibody-Drug Conjugates as Targeted Therapy for Treating Gynecologic Cancers: Update 2025 https://pubmed.ncbi.nlm.nih.gov/39480912/
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.